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and palonosetron-induced NK1 receptor internalization 
in NG108-15 cells and that when used together receptor 
internalization was additive. Palonosetron-induced NK1 
receptor internalization was dependent on the presence of 
the 5-ht3 receptor. Results provide a possible explanation 
for palonosetron’s enhancement of the inhibition of the sP 
response and suggest that the effect of palonosetron and 
NK1 receptor antagonists on prevention of delayed emesis 
could be additive.
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Introduction
current therapy for the treatment of severe forms of 
chemotherapy-induced nausea and vomiting (cINV) 
caused by drugs like cisplatin includes the use of both 
5-ht3 and NK1 receptor antagonists along with dexa-
methasone (Roila et al. 2010; Basch et al. 2011; Ettinger 
et al. 2012). Even though several neurotransmitters and 
their corresponding receptors have been associated with 
the pathogenesis of emesis (Darmani et al. 2009; Darmani 
and Ray 2009), acute cINV has been largely ameliorated 
with 5-ht3 receptor antagonists, while aprepitant, an 
NK1 receptor antagonist, was shown to improve overall 
antiemetic efficacy including delayed emesis (hesketh 
et al. 2003; Darmani and Ray 2009; Feyer and Jordan 
2011). Even though a majority of patients are fully pro-
tected against cINV by the use of these therapies, there 
are still a significant number of patients that experience 
nausea and delayed emesis, especially following highly 
or moderately emetogenic chemotherapies (Feyer and 
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Jordan 2011). Netupitant is a potent and selective NK1 
receptor antagonist (Rizzi et al. 2012) currently in phase 
III clinical trials in combination with a fixed dose of palo-
nosetron for the prevention of cINV. Palonosetron is the 
only 5-ht3 receptor antagonist that has been found to be 
effective in both acute and delayed cINV after moderate 
emetogenic chemotherapy (Eisenberg et al. 2003; Gralla 
et al. 2003; aapro et al. 2006; saito et al. 2009). since 
palonosetron does not bind to the NK1 receptor (Wong 
et al. 1995), the mechanism behind palonosetron’s unique 
efficacy among 5-ht3 receptor antagonists against nau-
sea and delayed emesis has been puzzling. Mechanism of 
action studies have shown that unlike other 5-ht3 recep-
tor antagonists, palonosetron exhibits allosteric interac-
tions, positive cooperativity and persistent inhibition of 
receptor function; it also triggers receptor internalization 
and inhibits signaling crosstalk between 5-ht3 and NK1 
receptors (Rojas et al. 2014). these molecular interactions 
may be responsible for palonosetron’s clinical profile. 
It is not clear however, if palonosetron’s suppression of 
delayed emesis would be synergistic, additive or obscured 
when used in combination with NK1 receptor antagonists. 
Recent studies using NG108-15 cells known to express 
both the 5-ht3 and NK1 receptors (Reiser and hampre-
cht 1989; Emerit et al. 1993) showed that netupitant and 
palonosetron exhibit a synergistic effect in the prevention 
of the NK1 receptor response against its endogenous ago-
nist substance P (stathis et al. 2012). the results suggest 
that palonosetron’s effect is distinct in the presence of an 
NK1 receptor antagonist at least in NG108-15 cells. In the 
present study, we began to explore the potential mecha-
nism behind the synergistic effect. We report that when 
used alone, both netupitant and palonosetron can trigger 
NK1 receptor internalization and that when used in com-
bination their effect becomes additive. NK1 receptor inter-
nalization could be a result of the previously observed 
5-ht3/NK1 receptor crosstalk inhibition by palonosetron 
(Rojas et al. 2010a).
Methods
Plasmid preparation and cell transfection
Plasmid preparation and cell transfection of hEK-293 cells 
to express NK1 receptors (NK1-hEK-293) cell have been 
described previously (Rojas et al. 2008).
antagonist concentrations
Unless otherwise noted, the concentration of each antago-
nist used was fivefold the Kd value reported in the litera-
ture to insure saturation of receptors. thus, concentrations 
of netupitant, palonosetron and ondansetron were 5, 1 and 
30 nM, respectively.
Binding of [3h]-netupitant after incubation of cells 
with unlabeled antagonists
[3h]-Netupitant binding to cells after preincubation with 
different antagonists was measured as outlined previ-
ously (Rojas et al. 2008). Briefly, NG108-15 cells or NK1-
hEK-293 cells were pretreated with antagonist(s) or saline 
(control) for 24 h. subsequent to each treatment, antago-
nists were removed, and fresh growth media were added to 
the cells; 2 h later, cells were incubated in fresh hEPEs-
buffered saline at room temperature for an additional 
30 min. the buffer was removed and cells incubated with 
[3h]-netupitant (5 nM) for 40 min at room temperature. at 
the end of the incubation period, media were removed and 
the cells were washed with ice-cold buffer. Following the 
wash, cells were lysed into 200 µl of fresh ice-cold buffer 
and the radioactivity associated with the cells was meas-
ured using a scintillation counter. student’s t test was used 
for statistical analyses of the results.
Dissociation of antagonists from cells
NG108-15 cells were incubated with [3h]-netupi-
tant ± palonosetron or ondansetron for 24 h. at the end of 
this incubation, antagonist-containing media were replaced 
with prewarmed hEPEs-buffered saline containing excess 
unlabeled netupitant (5 µM) and dissociation of [3h]-netu-
pitant at 37 °c was followed at 0, 2.5, 5, 7.5, 15, 30, 60 and 
120 min. after removing medium, cells were scraped into 
200 µl of fresh ice-cold buffer, and the radioactivity present 
in the scraped material at each time point was measured 
using a scintillation counter. student’s t test was used for 
statistical analyses of the results.
Dissociation of antagonists from cell-free membranes
Preparation of cell-free membranes and kinetic disso-
ciation experiments using cell-free membranes have been 
described previously (Wong et al. 1995; Rojas et al. 2008). 
Briefly, the association phase was conducted in a 96-well 
glass plate (Zinsser Na, Northridge, ca) by incubating 
NG108-15 cell membranes prepared from ~100,000 cells 
with [3h]-netupitant ± palonosetron or ondansetron in 
tris-Krebs buffer (ph 7.4 at 37 °c) for 90 min at 37 °c. 
the dissociation phase was then initiated by addition of 
excess unlabeled netupitant (1 μM). the amount of [3h]-
netupitant bound to the receptor was measured at various 
times during the first hour after addition of displacer. Prism 
(GraphPad software Inc, san Diego, ca) was used to 
obtain half-life values.
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acid treatment
the acid treatment protocol was based on published 
methodology (haigler et al. 1980). NG108-15 cells 
were incubated with [3h]-netupitant ± palonosetron or 
ondansetron for 24 h. at the end of this period, media 
were removed and cells were incubated with saline 
(0.5 M Nacl) containing acetic acid (0.2 M, ph 2.5) for 
6 min on ice. acid denaturation of cell surface proteins 
was terminated with the addition of one volume of ice-
cold hEPEs-buffered saline (ph 7.4). cells were then 
washed once with the same buffer. Radioactivity present 
in the cells was measured with a scintillation counter, 
and percent radioactivity in the cell fraction was calcu-
lated. Radioactivity present in washes was also measured 
to confirm that the radioactivity recovery was close to 
100 % in each case. student’s t test was used for statisti-
cal analysis of the results.
Protease treatment
the protease treatment protocol was adapted from the 
literature (simantov and sachs 1973). Briefly, NG108-15 
cells were incubated with [3h]-netupitant ± palonosetron 
or ondansetron for 24 h. at the end of this period, media 
were removed and cells were incubated with hEPEs-
buffered saline containing trypsin (2.5 mg/ml) for 5 min 
at 37 °c. Digestion by trypsin was terminated by washing 
cells twice with ice-cold hEPEs-buffered saline contain-
ing limabean trypsin inhibitor (50 µg/ml). Radioactiv-
ity present in each wash and in the cells was determined 
with a scintillation counter, and percent radioactivity in 
the cell fraction was calculated. a control experiment 
was carried out to measure dissociation of antagonists 
from cells, in the absence of proteases, under similar 
experimental conditions. student’s t test was used for sta-
tistical analysis.
Results
Preincubation of NG108-15 cells with netupitant 
plus palonosetron additively reduced [3h]-netupitant 
binding
When NG108-15 cells expressing both 5-ht3 and NK1 
receptors were pretreated with either netupitant (5 nM) or 
palonosetron (1 nM), subsequent binding of [3h]-netupitant 
was reduced, respectively, by 14 ± 0.7 and 10 ± 0.4 % 
compared with binding by control cells that had not been 
preincubated with antagonist. Further, when cells were 
preincubated with the two antagonists, reduction in bind-
ing was additive: 29 ± 1.7 % (Fig. 1a). In contrast, when 
NG108-15 cells were pretreated with ondansetron (30 nM), 
there was no reduction in binding compared with control 
cells (0 ± 1.4 %). Moreover, when ondansetron was prein-
cubated with netupitant, reduction in binding was the same 
as when using netupitant only (17 ± 2 %) (Fig. 1a).
Interestingly, when using NK1-hEK-293 cells that 
express the NK1 receptor but not the 5-ht3 receptor, prein-
cubation with palonosetron did not reduce subsequent [3h]-
netupitant binding (Fig. 1b). however, preincubation with 
netupitant reduced [3h]-netupitant binding by 15 ± 1 %, 
but when palonosetron and netupitant were preincubated 
Fig. 1  Reduction in binding of [3h] netupitant after incubation of 
cells with NK1 and 5-ht3 receptor antagonists. Reduction in binding 
in a NG108-15 cells expressing both NK1 and 5-ht3 receptors and 
b NK1-hEK-293 cells expressing NK1 receptors only—cells were 
preincubated ± antagonist (s) for 24 h as indicated. Netu: netupitant 
(5 nM); Palo: palonosetron (1 nM); Netu + Palo: netupitant (5 nM) 
plus palonosetron (1 nM); Ond: ondansetron (30 nM); Netu + Ond: 
netupitant (5 nM) plus ondansetron (30 nM). cells were washed to 
remove the antagonists and subsequently incubated with [3h] netu-
pitant for 40 min at room temperature. at the end of the incubation 
period, unbound [3h] netupitant was removed, and the radioactiv-
ity associated with the cells was measured (methods). Radioactivity 
associated with control cells was normalized to 100 %. Percent bind-
ing with respect to control cells for each treatment was subtracted 
from 100 to obtain the reduction in binding shown on the y-axis. 
Error bars correspond to standard deviation of three independent 
experiments run in triplicate. ***p < 0.001 when compared to netupi-
tant; student’s t test was used for statistical analysis
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together with NK1-hEK293 cells, reduction in binding 
was the same as when using netupitant only (13 ± 2 %) 
(Fig. 1b).
acid treatment of NG108-15 cells preincubated 
with [3h]-netupitant plus palonosetron showed additive 
association of [3h]-netupitant with cells
When cells are incubated with [3h] ligand that binds to a 
receptor followed by removal of media and limited acid 
treatment, the acid partially disrupts cell membranes. 
this disruption removes [3h] ligand that could be buried 
within the cell membrane leaving only radiolabeled mate-
rial that is truly inside cells. the presence of radiolabeled 
material inside cells after acid treatment is indicative of 
receptor internalization (haigler et al. 1980; Rojas et al. 
2010b). accordingly, when NG108-15 cells were incu-
bated with [3h]-netupitant followed by limited expo-
sure to acetic acid, the percent of [3h]-netupitant associ-
ated with cells was 14 ± 0.5 % compared to when cells 
were only washed with cold buffer, but not treated with 
acid. When both [3h]-netupitant and palonosetron were 
used, the percent of [3h]-netupitant associated with cells 
became additive: 28 ± 1.4 % (table 1). In contrast, the 
use of ondansetron with [3h]-netupitant did not increase 
the amount of radiolabel associated with the cells 
(13 ± 0.1 %) (table 1).
Protease treatment of NG108-15 cells preincubated 
with [3h]-netupitant plus palonosetron showed additive 
association of [3h]-netupitant with cells
When cells are incubated with [3h] ligand that binds 
to a receptor followed by removal of media and lim-
ited protease (trypsin) treatment, the protease partially 
hydrolyzes proteins present on the cell membranes. this 
partial hydrolysis denatures the proteins and removes 
[3h]-netupitant that could be pseudo irreversibly bound 
to the receptor within the cell membrane. as a result, 
any [3h]-netupitant that is associated with cells is [3h]-
netupitant that is truly inside cells. the presence of radi-
olabeled material inside cells after protease treatment is 
indicative of receptor internalization (simantov and sachs 
1973; Rojas et al. 2010b). accordingly, when NG108-15 
cells were incubated with [3h]-netupitant followed by 
limited exposure to trypsin, the percent of [3h]-netupitant 
associated with cells was 14 ± 0.8 % compared to when 
cells were only washed with cold buffer but not treated 
with trypsin. When both [3h]-netupitant and palonose-
tron were used, the percent of [3h]-netupitant associated 
with cells became additive: 27 ± 0.1 % (table 1). In con-
trast, the use of ondansetron with [3h]-netupitant did not 
increase the amount of radiolabel associated with the cells 
(13 ± 1 %) (table 1).
the extent of [3h]-netupitant associated with cells 
is increased in the presence of palonosetron, but not 
ondansetron
If [3h]-netupitant goes inside cells as part of a [NK1 recep-
tor-[3h]-netupitant] complex, it would not be available for 
dissociation. accordingly, we studied dissociation of [3h]-
netupitant from NG108-15 cells after allocating time for 
internalization (24 h) ± palonosetron or ondansetron. the 
percent of [3h]-netupitant that remained associated with 
cells after 1 h under dissociation conditions was 24 ± 2 % 
of the radioactive material associated with cells at the 
beginning of dissociation (Fig. 2a and table 2). When cells 
were preincubated with [3h]-netupitant plus palonosetron, 
the percent of [3h]-netupitant that remained associated 
with cells increased almost twofold to 45 ± 0.6 % (Fig. 2a 
and table 2), an indication of increased [NK1 receptor-
[3h]-netupitant] complex internalization. In contrast, when 
cells were preincubated with [3h]-netupitant plus ondan-
setron, the percent of [3h]-netupitant that remained asso-
ciated with cells remained the same as when preincubat-
ing with [3h]-netupitant alone: 25 ± 0.2 % (Fig. 2a and 
table 2). Dissociation from cells in every case reached a 
plateau at 1 h and remained the same at 2 h (Fig. 2). the 
half-life of dissociation of [3h]-netupitant from cells was 
the same within error for the three treatments (~5 min) 
(table 2).
Table 1  acid treatment—NG108-15 cells were incubated for 24 h 
with [3h]-netupitant (5 nM), [3h]-netupitant (5 nM) plus palonose-
tron (1 nM) or [3h]-netupitant (5 nM) plus ondansetron (30 nM). after 
incubation, media were removed and cells were exposed to acetic acid 
ph 2.5 for 6 min on ice or to saline containing trypsin for 5 min at 
37 °c. cells were washed twice to remove radioactivity released into 
buffer and radioactivity remaining with cells was measured. Values 
listed are percent of [3h]-netupitant remaining with cells compared to 
cells that were washed with cold buffer but did not undergo acid or 
protease treatment. Data are the average of at least three independent 
determinations run in triplicate ± standard deviation
*** p < 0.001 when compared to [3h]-netupitant
Percent [3h]-netupitant  
remaining with cells  
after acid treatment
Percent [3h]-netupi-
tant remaining with  
cells after protease  
treatment
[3h]Netupitant 14 ± 0.5 14 ± 0.8
[3h]-Netupitant plus  
palonosetron
28 ± 1.4*** 27 ± 0.1***
[3h]Netupitant plus  
ondansetron
13 ± 0.1 13 ± 1
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the extent of [3h]-netupitant dissociation from cell-free 
membranes is the same in the presence or absence 
of palonosetron or ondansetron
If cell-free membranes are used in dissociation experiments, 
no internalization into cells is possible, and the extent of 
dissociation should be the same for all antagonists. accord-
ingly, when cell-free membranes isolated from NG108-15 
cells were incubated with [3h]-netupitant ± palonosetron 
or ondansetron, the extent of dissociation was the same for 
all three treatments (Fig. 2b). as expected, dissociation of 
[3h]-netupitant was close to 100 % except for some resid-
ual non-specific binding of netupitant (Fig. 2b). the half-
life of dissociation of [3h]-netupitant from cell membranes 
was the same within experimental error for all three treat-
ments (~4 min) (table 2).
Discussion
Previous studies have shown that palonosetron, in contrast 
to ondansetron and granisetron, causes 5-ht3 receptor 
internalization and inhibits sP-mediated responses in vitro 
and in vivo possibly as a result of inhibition of 5-ht3/NK1 
receptor cross talk (Rojas et al. 2014). these results gave 
a tentative rationale for palonosetron’s improved ability 
among 5-ht3 receptor antagonists to prevent nausea and 
delayed emesis after moderate emetogenic chemotherapy. 
In any case, given the inhibition of delayed emesis by NK1 
receptor antagonists, it is not clear if palonosetron’s inhi-
bition of delayed emesis would make any difference if 
co-administered with an NK1 receptor antagonist. Recent 
studies using NG108-15 cells that express both the NK1 
and 5-ht3 receptors showed synergistic inhibition of the 
substance P response by palonosetron and netupitant (sta-
this et al. 2012). the mechanism of this combined inhibi-
tion of the sP response is not known. One possible expla-
nation is that in addition to direct antagonism of the NK1 
receptor by netupitant, palonosetron could exert an indirect 
regulatory effect on the NK1 receptor after antagonizing the 
5-ht3 receptor. a case of a ligand binding to one receptor 
and triggering internalization of another receptor has been 
reported previously: NMDa binding to the NMDa recep-
tor triggers internalization of the GaBaB receptor (Guetg 
et al. 2010). We present three independent lines of evidence 
to show that NK1 receptor internalization can be triggered 
by netupitant or palonosetron, but not by ondansetron. We 
also show that NK1 receptor internalization by netupitant 
and palonosetron is additive and that palonosetron-trig-
gered NK1 receptor internalization requires the presence 
of 5-ht3 receptors. First, binding of [3h]-netupitant was 
reduced after prior exposure to netupitant or palonose-
tron, but not ondansetron (Fig. 1). second, [3h]-netupitant 
remained with cells following incubation with [3h]-netupi-
tant ± palonosetron and subsequent acid or protease treat-
ments. When palonosetron was present, [3h]-netupitant 
association with cells was increased. In contrast, when 
using ondansetron, the amount of [3h]-netupitant associa-
tion with cells was the same as when using [3h]-netupitant 
alone (table 1). Finally, dissociation of [3h]-netupitant 
from cells was significantly reduced in the presence of 
Fig. 2  Dissociation of [3h]-netupitant ± palonosetron or ondan-
setron from NG108-15 cells (a) and cell-free membranes (b). cells 
were preincubated for 24 h with [3h]-netupitant (5 nM), [3h]-net-
upitant (5 nM) plus palonosetron (1 nM) or [3h]-netupitant (5 nM) 
plus ondansetron (30 nM). at the end of this incubation, antagonist-
containing media were replaced with prewarmed hEPEs-buffered 
saline containing excess unlabeled netupitant (5 µM) and dissociation 
of [3h]-netupitant at 37 °c was followed at different times as shown. 
after removing medium, cells were scraped into 200 µl of fresh ice-
cold buffer, and the radioactivity present in the scraped material at 
each time point was measured using a scintillation counter. When 
using cell-free membranes the association phase was carried out for 
90 min (24 h gave same results) at 37 °c. the dissociation phase was 
then initiated by addition of excess unlabeled netupitant (1 μM). the 
amount of [3h]-netupitant bound to the receptor was measured at 
various times during the first hour after addition of displacer. Prism 
(GraphPad software Inc, san Diego, ca) was used to obtain half-life 
values
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palonosetron, but not ondansetron. In contrast, when using 
cell-free membranes where no receptor internalization can 
occur, the extent of dissociation of [3h]-netupitant was the 
same ± palonosetron or ondansetron (Fig. 2).
NK1 receptor internalization by netupitant and by palon-
osetron provides a rationale on how these antagonists could 
be acting in concert to help prevent NK1 receptor activa-
tion by substance P in NG108-15 cells (stathis et al. 2012). 
this rationale is illustrated in Fig. 3. Previously, we have 
shown that palonosetron can induce 5-ht3 receptor inter-
nalization (Rojas et al. 2010b). Further, work in other labo-
ratories has shown that there is receptor cross talk between 
5-ht3 and NK1 receptor pathways (Minami et al. 2001; hu 
et al. 2004). It is possible that 5-ht3 receptor internaliza-
tion induced by palonosetron alters this receptor cross 
talk, resulting in NK1 receptor internalization. In parallel, 
netupitant also triggers NK1 receptor internalization. Both 
events lead to reduced density of NK1 receptors on the cell 
surface; since palonosetron and netupitant trigger receptor 
internalization only partially, it is possible for NK1 inter-
nalization to be additive and inhibition of downstream sign-
aling like substance P-induced calcium ion mobilization to 
be synergistic (stathis et al. 2012). We are currently explor-
ing effects on phosphorylation by these antagonists in an 
effort to further elucidate the effects of these drugs on the 
crossroads of these two signaling systems.
It is important to remember that NG108-15 cells are a 
rodent-derived cell model used to explore the potential 
mechanism of action on delayed emesis when using palo-
nosetron and netupitant in humans. consequently, the 
results obtained in these studies are only a tentative expla-
nation of the more complex mechanism in humans. While 
the use of 5-ht3 and NK1 rodent receptors has been useful 
in the early characterization of palonosetron (Wong et al. 
1995) and netupitant (Rizzi et al. 2012) before they went 
to the clinic, there are differences between the receptors 
in the two species that could be relevant to their mecha-
nism of action in the two species. For example, the affin-
ity of rodent NK1 receptor antagonists is lower than in 
humans (tattersall et al. 2000; Rizzi et al. 2012). In addi-
tion, even though both rodents and humans exhibit 5-ht3a 
and 5-ht3B receptor subunits, humans also have 5-ht3c-
E subunits that could conceivably alter the response to the 
antagonists (lummis 2012).
Table 2  Rate and extent of dissociation in cells and cell-free membranes—values of half lives correspond to the traces in Fig. 2. Graph Pad 
PRIsM® was used to obtain half lives using the best fit of a single phase exponential decay. Data are the average of four experiments. Errors cor-
respond to ± sEM
*** p < 0.001 when compared to [3h]-netupitant
treatment %[3h]-Netupitant associated with 
cells after dissociation levels off 
(120 min)
half-life of [3h]- Netupitant bound 
to cells (min)
half-life of [3h]- Netupitant 
bound to cell-free membranes 
(min)
[3h]- Netupitant 24 ± 2 5.7 ± 0.3 (n = 3) 4.7 ± 0.2 (n = 2)
[3h]- Netupitant + palonosetron 45 ± 0.6*** 4.6 ± 0.2 (n = 3) 4.3 ± 0.8 (n = 3)
[3h]- Netupitant + ondansetron 25 ± 0.2 5.6 ± 0.11 (n = 3) 3.5 (n = 1)
Fig. 3  Effects of netupitant and palonosetron in NG108-15 cells—
Receptor internalization can be induced through direct binding of 
palonosetron to the 5-ht3 receptor (1) and of netupitant to the NK1 
receptor (2). Internalization of either receptor could lead to altera-
tions in receptor signaling cross talk (3). NK1 receptor internalization 
would result in lower NK1 receptor density at the cell surface that in 
turn desensitizes NK1 signaling (4). NK1 receptor internalization can 
be induced by netupitant (directly and possibly indirectly) or by palo-
nosetron (indirectly)
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In summary, three independent lines of evidence indicate 
that both netupitant and palonosetron can trigger NK1 recep-
tor internalization in NG108-15 cells. Netupitant exerts its 
effect through direct binding, whereas palonosetron does it 
through a 5-ht3 receptor-mediated effect. When both antag-
onists are used, receptor internalization becomes additive. 
5-ht3 and NK1 receptor internalization by both netupitant 
and palonosetron provide additional information in the effort 
to arrive to a mechanistic explanation of the additive and syn-
ergistic effects on the NK1 receptor antagonism when a com-
bination of netupitant and palonosetron is used in these cells.
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